Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Arecor, Lilly Sign Formulation Study Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Arecor, Lilly Sign Formulation Study Partnership

Arecor will use its proprietary formulation technology platform to develop a differentiated, thermostable formulation of one of Lilly’s proprietary products.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Arecor Limited, the biopharmaceutical company, has signed a formulation study partnership with Eli Lilly and Company (Lilly).
 
Under this agreement, Arecor will use its proprietary formulation technology platform Arestat to develop a differentiated, thermostable formulation of one of Lilly’s proprietary products intended for self-administration. The thermostable formulation will allow greater convenience of use of the product by patients, whilst maintaining its integrity.
 
Lilly will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model to further develop and commercialize the product.
 
Arestat is a proprietary formulation technology platform which enhances the properties of therapeutic proteins, peptides and vaccines. Arecor applies the Arestat technology to deliver superior reformulations of existing products as well as improving properties of new products in development.
 
Sarah Howell, chief executive officer of Arecor, commented, “We are delighted to be collaborating with Lilly again. We have always had a strong working relationship and we believe that our Arestat technology has the potential to deliver a new formulation that can improve the convenience of use of this critical self-administered product for Lilly’s patients. This collaboration with Lilly augments our partnership portfolio of major pharmaceutical companies and demonstrates how our formulation expertise can provide novel medical solutions for our partners.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics